Hospital morphine preparation for abstinence syndrome in newborns exposed to buprenorphine or methadone

Pharmacy World and Science

Volumn 30, Issue 3, 2008, Pages 227-234

  Colombini, Nathalie ^a   Elias, Riad ^a   Busuttil, Muriel ^a   Dubuc, Myriam ^a   Einaudi, Marie Ange ^a   Bues Charbit, Martine ^a  

^a HÔPITAL NORD   (France)

Author keywords

Buprenorphine; Methadone; Morphine; Neonatal abstinence syndrome; Opioid dependence; Withdrawal

Indexed keywords

BUPRENORPHINE; METHADONE; MORPHINE;

ARTICLE; BIRTH WEIGHT; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EXPOSURE; FEMALE; GESTATIONAL AGE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFANT; MALE; MICROBIOLOGICAL EXAMINATION; PREGNANCY; TREATMENT DURATION; WITHDRAWAL SYNDROME;

BUPRENORPHINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CONTAMINATION; DRUG STABILITY; FEMALE; HUMANS; INFANT, NEWBORN; METHADONE; MORPHINE; NARCOTIC ANTAGONISTS; NARCOTICS; NEONATAL ABSTINENCE SYNDROME; PHARMACEUTICAL SOLUTIONS; PREGNANCY; PROSPECTIVE STUDIES;

EID: 42249094377     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-007-9176-1     Document Type: Article

References (34)

1. Cairns PA. Drug misuse: conception into childhood. Curr Paediatr 2001;11:475-79.
2. Ferraro F, Massard A. Conséquences de la toxicomanie à la cocaïne pendant la grossesse sur le développement de l'enfant. [Consequences of cocaïne addiction during pregnancy on the development in the child]. Arch Pediatr 1997;4(7):677-82.
3. Lejeune C, Floch-Tudal C, Montamat S, Crenn-Hebert C, Simonpoli AM. Prise en charge des femmes enceintes toxicomanes et de leurs enfants. [Management of drug addict pregnant women and their children]. Arch Pediatr 1997;4(3):263-70.
4. Sinha C, Ohadike P, Carrick P, Pairaudeau P, Armstrong D, Lindow SW. Neonatal outcome following maternal opiate use in late pregnancy. Int J Gynaecol Obstet 2001;74:241-6.
5. Regini P, Cutrone M, Donzelli F, Flora PG, Montesanto G. Neonatal buprenorphine withdrawal syndrome; what is the right therapy? Pediatr Med Chir 1998;20:67-9.
6. Marquet P. Pharmacologie périnatale des opiacés. [Perinatal pharmacology of opiates] Arch Pediatr 2000;7(Suppl 2):287s-89s.
7. Theis JG, Selby P, Ikizler Y, Koren G. Current management of the neonatal abstinence syndrome: a critical analysis of the evidence. Biol Neonate 1997;71:345-56.
8. American Academy of Pediatrics. Committee On Drugs. Neonatal drug withdrawal. Pediatrics 1998;101:1079-88.
9. Coghlan D, Milner M, Clarke T, Lambert I, McDermott C, McNally M, et al. Neonatal abstinence syndrome. Med J 1999;92(1):232-6.
10. Coyle MG, Ferguson A, Lagasse L, Ob W, Lester B. Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants. J Pediatr 2002;140:561-4.
11. Johnson RE, Jones HE, Fischer G. Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug Alcohol Depend 2003;70:S87-101.
12. Amirat-Combralier V, Jentile B, Elias R, Dejode JM, Lagier P, Bues-Charbit M, et al. Preparation and use of morphine capsules in paediatric patients with burns. J Pharm Belg 1997;52(6):217-8.
13. Anderson IB, Kearney TE. Use of methadone. West J Med 2000;172:43-6.
14. Ward J, Hall W, Mattick RP. Role of maintenance treatment in opioid dependence. Lancet 1999;353:221-6.
15. Osborn DA, Jeffery HE, Cole MJ. Sedatives for opiate withdrawal in newborn infants. In: National Institute of Child Health and Human Development, 2002. http://www.nichd.nih.gov/cochrane (15 February 2005).
16. Lipsitz PJ. A proposed narcotic withdrawal score for use with newborn infants: a pragmatic evaluation of its efficacy. Clin Pediatr 1975;14:592-4.
17. Perelman R, Amiel-Tison CL, Desbois JC. Périnatologie- Pédiatrie pratique. [Practical perinatology and paediatrics]. Paris: Imprimerie Maloine; 1985.
18. Kandall SR, Gaines J. Maternal substance use and subsequent sudden infant death syndrome (SIDS) in offspring. Neurotoxicol Teratol 1991;13(2):235-40.
19. Marquet P. Pharmacology of opiates during pregnancy. In: Kintz P, Marquet P, editors. Buprenorphin therapy of opiate addicts. Totowa-New Jersey: Human Press; 2002.p. 119-24.
20. Jernite M, Viville B, Escande B, Brettes JP, Messer J. Grossesse et buprénorphine, à propos de 24 cas. [Buprenorphine and pregnancy. Analysis of 24 cases]. Arch Pediatr 1999;11:1179-85.
21. Levy M, Spino M. Neonatal withdrawal syndrome: associated drugs and pharmacologic management. Pharmacotherapy 1993;13:202-11.
22. Lejeune C, Simmat-Durand L, Aubisson S, Gourarier L, Picquet M. Grossesse et substitution. Enquête sur les femmes enceintes substituées à la méthadone ou à la buprénorphine haut dosage et caractéristiques de leurs nouveau-nés. Observatoire Français des Drogues et des Toxicomanies (OFDT) [Pregnancy and substitutive treatment. Report on pregnant women treated by methadone or high dose buprenorphine and newborn characteristics. In: French Monitoring Center for Drugs and Drug Addiction (OFDT) library]. 2003. http://www.ofdt.fr/BDD/ publications/docs/epfxclj7.pdf (15 February 2005).
23. Micard S, Brion F. Prise en charge du syndrome de sevrage du nouveau-né de mère toxicomane aux opiacés: enquête française et européenne. [Management of the opioid withdrawal in the neonates: French and European survey] Arch Pediatr 2003;10(3):199-203.
24. Sutton LR, Hinderliter SA. Diazepam abuse in pregnant women on methadone maintenance. Implications for the neonate. Clin Pediatr 1990;29:108-11.
25. Dashe JS, Jackson GL, Olscher DA, Zane EH, Wendel GD. Opioid detoxification in pregnancy. Obstet Gynecol 1998;92(5):854-58.
26. Mazurier E, Sarda P, Boulot P. Traitement par Buprénorphine (Temgésic®) de la dépendance aux opiacés chez la femme enceinte. 26è Journées Nationales de la Société Française de Médecine Périnatale. [Treatment of opioid dependence in pregnant woman using Buprenorphine (Temgesic®). In: 26th Congress of the French Society of Perinatology] [Proceedings]. Brest (France), 1996.
27. Fischer G, Etzersdorfer P, Eder H, Jagsch R, Langer M, Weninger M. Buprenorphine maintenance in pregnant opiate addicts. Eur Addict Res 1998;4:32-6.
28. Fischer G, Johnson RE, Eder H, Jagsch R, Peternell A, Weninger M, et al. Treatment of opioid-dependent pregnant women with buprenorphine. Addiction 2000;95:239-44.
29. Johnson RE, Jones HE, Jasinski DR, Svikis DS, Haug NA, Jansson LM, et al. Buprenorphine treatment of pregnant opioid-dependent women: maternal and neonatal outcomes. Drug Alcohol Depend 2001;63(1):97-103.
30. Nanovskaya T, Deshmukh S, Brooks M, Ahmed MS. Transplacental transfer and metabolism of buprenorphine. J Pharmacol Exp Ther 2002;300(1):26-33.
31. Tran JH. Treatment of neonatal abstinence syndrome. J Pediatr Health Care 1999;13(6):295-300.
32. Choo RE, Huestis MA, Schroeder JR, Shin AS, Jones HE. Neonatal abstinence syndrome in methadone-exposed infants is altered by level of prenatal tobacco exposure. Drug Alcohol Depend 2004;75(3):253-60.
33. Auerbach JG, Hans SL, Marcus J, Maeir S. Maternal psychotropic medication and neonatal behavior. Neurotoxicol Teratol 1992;14(6):399-406.
34. Lundsberg LS, Bracken MB, Saftlas AF. Low-to-moderate gestational alcohol use and intra-uterine growth retardation, low birthweight, and pre-term delivery. Ann Epidemiol 1997;7(7):498-508.